Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This entity represents a combination of two ophthalmic lubricant brands, Systane Nighttime and Tears Again Ointment, with the antifungal agent miconazole nitrate and the skin protectant zinc oxide. Systane Nighttime and Tears Again Ointment are typically formulated with white petrolatum and mineral oil to provide an occlusive barrier that prevents moisture loss from the ocular surface, treating symptoms of dry eye. Miconazole nitrate is an imidazole antifungal that inhibits the synthesis of ergosterol by targeting the fungal enzyme lanosterol 14-alpha-demethylase, thereby disrupting cell membrane integrity. Zinc oxide serves as a mild astringent and topical barrier, commonly used to treat or prevent skin irritation. The inclusion of zinc oxide, which is generally not used in ophthalmic preparations due to potential irritation, suggests this combination may be a list of separate products or a specific compounded topical formulation rather than a standard commercial ophthalmic drug.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Systane Nighttime Tears Again Ointment + miconazole nitrate + zinc oxide.